Bidlingmaier, F.

Fink, R.

Knorr, D.

Müller, O. A.

Scriba, Peter Christian

Weil, J.

English

Universität München: Elektronischen Publikationen

endocrino 
logica 
Supplementum 225 
Advance Abstracts 
of 
Papers 
XII Acta Endocrinologica Congress 
Munich 
June 26-30,1979 
PERIODICA • C O P E N H A G E N 1979 
Eigentum der 
M ü n c h e n 
G E N E R A L C O N T E N T S 
Contents in detail IV 
Time-Table VI 
Poster Sess ions 1 -353 
Short Commun ica t i on S e s s i o n s - O r a l Presentat ion 3 5 4 - 4 1 3 
Sympos ia 4 1 4 - 4 8 7 
Plenary Lectures 4 8 8 - 4 9 3 
Anwards 4 9 4 - 5 1 3 
Authors ' Index 5 1 5 - 5 2 7 
P R O G R A M M E ORGANIZING COMMITTEE 
Cha i rman: J . Zander (München) 
Secretary: P. C. Sc r i ba (München) 
F. B id l ingmaier (München) 
M. Breckwold t (Freiburg) 
O. Butenandt (München) 
R. C laus (München-Weihenstephan) 
J . Hammerstein (Berlin) 
K. D. Hepp (München) 
P. W. Jungblu t (Wi lhelmshaven) 
H. Karg (München-Weihenstephan) 
D. Knorr (München) 
R. Landgraf (München) 
H. Mehnert (München) 
H. M ickan (München) 
E. F. Pfeiffer (Ulm) 
C. Renate Pickardt (München) 
D. S c h a m s (München-Weihenstephan) 
Rosmar ie Vogel (München) 
K. von Werder (München) 
W.Wuttke (Gött ingen) 
R. Ziegler (Ulm) 
III 
CONTENTS 
Abstract numbers 
POSTER SESSIONS I, II, III a n d p a g e s 
Thyroid 1 - 26 
T S H a n d T S I 2 7 - 47 
Adrenal 4 8 - 56 
A C T H and Related Pept ides 5 7 - 81 
Testis 8 2 - 96 
Ovary 9 7 - 1 1 4 
Pregnancy 115-120 
Puberty 121 -128 
Gonadotrophi ns 129 - 1 5 7 
Prolact in 158 -187 
Growth Hormone 188 -200 
Pituitary Tumor 201 - 2 0 5 
O x y t o c i n / A D H 2 0 6 - 2 1 8 
Hypothalamus 2 1 9 - 2 3 6 
P inea l /B ra i n Hormones 2 3 7 - 2 4 4 
Hormonal Effects on C N S / B e h a v i o u r 2 4 5 - 2 5 3 
Comparat ive Endoc r i no logy /Phe romones 2 5 4 - 2 6 0 
Receptors - Sexual Steroids 261 - 2 8 0 
Receptors - Cort icostero ids 281 - 2 8 6 
Receptors - Proteohormones 287-301 
Metabol ism / Obesity 302-321 
Gastrointest inal Hormones 3 2 2 - 3 2 5 
Parathyr in /V i tamin D /Ca lc i t on in 3 2 6 - 3 3 5 
Hypertension 3 3 6 - 3 5 3 
SHORT COMMUNICATION SESSIONS 1-6 
- ORAL PRESENTATION 
S C 1a Gonadot roph ins 3 5 4 - 3 5 8 
S C 1b Ovary /P lacen ta 3 5 9 - 3 6 3 
S C 2a Thyroid 3 6 4 - 3 6 9 
S C 2b Hypothalamic Hormones 3 7 0 - 3 7 3 
S C 3a A C T H and Related Pept ides 3 7 4 - 3 7 9 
S C 3b Hypertension 3 8 0 - 3 8 3 
S C 4a Stero ids: Metabol ism, Effect 3 8 4 - 3 8 9 
S C 4b Hypogonadism 3 9 0 - 3 9 3 
S C 5a Pro lac t in /Growth Hormone 3 9 4 - 3 9 9 
S C 5b Parathyrin 4 0 0 - 4 0 3 
S C 6a Metabo l ism/Gast ro in tes t ina l Hormones 4 0 4 - 4 0 8 
S C 6b Antidiuret ic Hormone 4 0 9 - 4 1 3 
IV 
SYMPOSIA 1-9 
Abstract / pages 
numbers 
S 1 Neuropept ides 414-- 4 1 8 / 4 1 4 - -422 
S 2 Phe romones 419--424 / 423--433 
S 3 The Insulin Receptor 425--429 / 434--441 
S 4 Progress in Thyro ido logy 430--434 / 442--449 
S 5 "K idney H o r m o n e s " in the Regulat ion 
of Vascu lar and Tubular Funct ions 435--439 / 450--456 
S 6 Sexua l D imorph ism 440--444 / 457--465 
S 7 Regulat ion of Gonadot roph in Secret ion 445--449 / 466--472 
S 8 Hormone Receptor Systems 450--454 / 473--480 
S 9 Progress in the Management of Disorders 
of Ca l c i um Metabo l ism and Bone Diseases 455-- 4 5 9 / 4 8 1 - -487 
PLENARY LECTURES 
B.T. P I C K E R I N G : Cel lu lar mechan ism of hormone 
synthesis, t ransport and release 460 / 488 
H. S T U D E R : Pathogenet ic mechan isms result ing 
in euthyroid and hyperthyroid, non- immunogen ic 
goiters 461 / 489 
W. J . IRVINE: Immunology of d iabetes mell i tus 
and other endocr ine d iseases 462 / 491 
F O U R T H G E O F F R E Y HARRIS M E M O R I A L L E C T U R E : 
B. F L E R K O : The hypophysia l portal c i rculat ion to-day 463 / 492 
A W A R D S O F T H E G E R M A N S O C I E T Y 
FOR E N D O C R I N O L O G Y 4 6 4 - 4 6 8 / 4 9 4 - 5 1 3 
V 
A c t a endoc r . (Kbh.) Supp l . 225 (1979) 
49 DIURNAL PLASMA-ACTH-LEVELS IN CORTICOSTEROID TREATED 
PATIENTS WITH CONGENITAL ADRENAL HYPERPLASIA (CAH) . 2 
O.A.Müller\ R.Fink , P.C.Scriba , J.Weil ,F^ Bidlingmaier 
and D.ffnorr . Medizinische K l i n i k Innenstadt and Kinder-
K l i n i k , U n i v e r s i t a e t Muenchen, FRG. 
The t h e r a p e u t i c a l c o n t r o l of CAH-patients by measuring a 
s i n g l e parameter of the s t e r o i d hormones i s c o n t r o v e r s i a l . The 
measurement of d i f f e r e n t adrenal androgens has not given the 
awaited u s e f u l r e s u l t s (1). The same has been seen f o r s i n g l e 
plasma-ACTH-levels (2). This study has measurgd thg oplasma-ACTH-
l e v e l s at d i f f e r e n t times during the day (08 ,12 ,18 ,24 ) 
to assess the t h e r a p e u t i c a l value o f 2 d i f f e r e n t c o r t i c o s t e r o i d s , 
c o r ^ j s o l ^F) and Qprednisone (P), usu a l l y given 3 times d a i l y 
(08 ,13 ,21 ). In a d d i t i o n , in the pat i e n t s with s a l t l o s s , 
9 a - F - c o r t i s o l was given. The d i u r n a l v a r i a t i o n of plasma-ACTH 
and 17ct-0H-progesterone (17-OHP) and F was examined i n 20 pa-
t i e n t s , 9 of which were re-examined a f t e r a l t e r a t i o n of therapy. 
Plasma-ACTH was measured by radioimmunoassay (RIA) a f t e r extrac-
t i o n (3). Plasma s t e r o i d s were measured by RIA a f t e r p r i o r 
chromatography on Sephadex LH-20 columns (4). 
RESULTS : ACTH-levels were on the whole glevated, with maximal 
values at 08°°, f a l l i n g to a minimum at 24 °. There was a s i g n i -
f i c a n t c o r r e l a t i o n between ACTH-levels and 17-OHP (n=114) a f t e r 
a logarithmic transformation (r=0.639, p<0.001) and an inverse 
c o r r e l a t i o n between ACTH and F (n=114, r= -0.255, p<0.01). For a 
b e t t e r comparison between d i f f e r e n t p a t i e n t s , the i n t e g r a l (I) 
under the ACTH curve over a 24h period was used (1= J " 2 4 ACTH (t) 
dt = X pg/ml ACTH). The value of I in CAH-patients ï n most cases' 
was much higher than in normals (I: 400-900, n=4). In F-treated 
p a t i e n t s I ranged from 220-8000 (n=17), in P-treated patients 
from 580-12100 (n=12), which was no s i g n i f i c a n t d i f f e r e n c e . The 
r a t i o F:P (given dose in mg) was 4-5 : 1. A better comparison i s 
obtained when I was c a l c u l a t e d f o r each p a t i e n t , who has under-
gone both F and P treatment (n=5). In 4 of these p a t i e n t s I i s 
much lower under F, whereas in the remaining one, under 12.5 mg 
F/day I = 5700, under 3 mg P/day I = 2573. In a f u r t h e r 4 pa-
t i e n t s under d i f f e r i n g doses of the same c o r t i c o s t e r o i d i t was 
oo 
found that in p a r t i c u l a r the evening dose (21 ) must not be too 
low, otherwise the ACTH-level on the following day (08 ) was 
exc e s s i v e l y high. 
CONCLUSION : The use of the ACTH-24h-integral, as described 
here, appears to be promising in the evaluation of therapy in 
CAH-patients. Furthermore the use of t h i s parameter in the same 
pat i e n t s r e c e i v i n g d i f f e r e n t c o r t i c o s t e r o i d s helps in the choice 
of t h e i r "optimal" medication. 
+ Supported by the Deutsche Forschungsgemeinschaft (Sonder-
forschungsbereich 51) and S t i f t u n g Volkswagenwerk (Az: 140194). 
1) Korth-Schutz S. et a l . : J.Clin.Endocrinol.Metab.46 (1978) 452 
2) Pham-Huu-Trung M.T. et a l . : J.Clin.Endocrinol.Metab.47(1978) 
3) Müller O.A.et a l . : GIT Labormedizin 2 (1978) 117 4 2 2 
4) Bidlingmaier F. et a l . : Pediatr.Res. 7 (1973) 901 
49 


Diurnal plasma-ACTH-levels in corticosteroid treated patients with congenital adrenal hyperplasia (CAH)

Open Access LMU

endocrino logica Supplementum 225 Advance Abstracts of Papers XII Acta Endocrinologica Congress Munich June 26-30,1979 PERIODICA • C O P E N H A G E N 1979 Eigentum der M ü n c h e n G E N E R A L C O N T E N T S Contents in detail IV Time-Table VI Poster Sess ions 1 -353 Short Commun ica t i on S e s s i o n s - O r a l Presentat ion 3 5 4 - 4 1 3 Sympos ia 4 1 4 - 4 8 7 Plenary Lectures 4 8 8 - 4 9 3 Anwards 4 9 4 - 5 1 3 Authors ' Index 5 1 5 - 5 2 7 P R O G R A M M E ORGANIZING COMMITTEE Cha i rman: J . Zander (München) Secretary: P. C. Sc r i ba (München) F. B id l ingmaier (München) M. Breckwold t (Freiburg) O. Butenandt (München) R. C laus (München-Weihenstephan) J . Hammerstein (Berlin) K. D. Hepp (München) P. W. Jungblu t (Wi lhelmshaven) H. Karg (München-Weihenstephan) D. Knorr (München) R. Landgraf (München) H. Mehnert (München) H. M ickan (München) E. F. Pfeiffer (Ulm) C. Renate Pickardt (München) D. S c h a m s (München-Weihenstephan) Rosmar ie Vogel (München) K. von Werder (München) W.Wuttke (Gött ingen) R. Ziegler (Ulm) III CONTENTS Abstract numbers POSTER SESSIONS I, II, III a n d p a g e s Thyroid 1 - 26 T S H a n d T S I 2 7 - 47 Adrenal 4 8 - 56 A C T H and Related Pept ides 5 7 - 81 Testis 8 2 - 96 Ovary 9 7 - 1 1 4 Pregnancy 115-120 Puberty 121 -128 Gonadotrophi ns 129 - 1 5 7 Prolact in 158 -187 Growth Hormone 188 -200 Pituitary Tumor 201 - 2 0 5 O x y t o c i n / A D H 2 0 6 - 2 1 8 Hypothalamus 2 1 9 - 2 3 6 P inea l /B ra i n Hormones 2 3 7 - 2 4 4 Hormonal Effects on C N S / B e h a v i o u r 2 4 5 - 2 5 3 Comparat ive Endoc r i no logy /Phe romones 2 5 4 - 2 6 0 Receptors - Sexual Steroids 261 - 2 8 0 Receptors - Cort icostero ids 281 - 2 8 6 Receptors - Proteohormones 287-301 Metabol ism / Obesity 302-321 Gastrointest inal Hormones 3 2 2 - 3 2 5 Parathyr in /V i tamin D /Ca lc i t on in 3 2 6 - 3 3 5 Hypertension 3 3 6 - 3 5 3 SHORT COMMUNICATION SESSIONS 1-6 - ORAL PRESENTATION S C 1a Gonadot roph ins 3 5 4 - 3 5 8 S C 1b Ovary /P lacen ta 3 5 9 - 3 6 3 S C 2a Thyroid 3 6 4 - 3 6 9 S C 2b Hypothalamic Hormones 3 7 0 - 3 7 3 S C 3a A C T H and Related Pept ides 3 7 4 - 3 7 9 S C 3b Hypertension 3 8 0 - 3 8 3 S C 4a Stero ids: Metabol ism, Effect 3 8 4 - 3 8 9 S C 4b Hypogonadism 3 9 0 - 3 9 3 S C 5a Pro lac t in /Growth Hormone 3 9 4 - 3 9 9 S C 5b Parathyrin 4 0 0 - 4 0 3 S C 6a Metabo l ism/Gast ro in tes t ina l Hormones 4 0 4 - 4 0 8 S C 6b Antidiuret ic Hormone 4 0 9 - 4 1 3 IV SYMPOSIA 1-9 Abstract / pages numbers S 1 Neuropept ides 414-- 4 1 8 / 4 1 4 - -422 S 2 Phe romones 419--424 / 423--433 S 3 The Insulin Receptor 425--429 / 434--441 S 4 Progress in Thyro ido logy 430--434 / 442--449 S 5 "K idney H o r m o n e s " in the Regulat ion of Vascu lar and Tubular Funct ions 435--439 / 450--456 S 6 Sexua l D imorph ism 440--444 / 457--465 S 7 Regulat ion of Gonadot roph in Secret ion 445--449 / 466--472 S 8 Hormone Receptor Systems 450--454 / 473--480 S 9 Progress in the Management of Disorders of Ca l c i um Metabo l ism and Bone Diseases 455-- 4 5 9 / 4 8 1 - -487 PLENARY LECTURES B.T. P I C K E R I N G : Cel lu lar mechan ism of hormone synthesis, t ransport and release 460 / 488 H. S T U D E R : Pathogenet ic mechan isms result ing in euthyroid and hyperthyroid, non- immunogen ic goiters 461 / 489 W. J . IRVINE: Immunology of d iabetes mell i tus and other endocr ine d iseases 462 / 491 F O U R T H G E O F F R E Y HARRIS M E M O R I A L L E C T U R E : B. F L E R K O : The hypophysia l portal c i rculat ion to-day 463 / 492 A W A R D S O F T H E G E R M A N S O C I E T Y FOR E N D O C R I N O L O G Y 4 6 4 - 4 6 8 / 4 9 4 - 5 1 3 V A c t a endoc r . (Kbh.) Supp l . 225 (1979) 49 DIURNAL PLASMA-ACTH-LEVELS IN CORTICOSTEROID TREATED PATIENTS WITH CONGENITAL ADRENAL HYPERPLASIA (CAH) . 2 O.A.Müller\ R.Fink , P.C.Scriba , J.Weil ,F^ Bidlingmaier and D.ffnorr . Medizinische K l i n i k Innenstadt and Kinder-K l i n i k , U n i v e r s i t a e t Muenchen, FRG. The t h e r a p e u t i c a l c o n t r o l of CAH-patients by measuring a s i n g l e parameter of the s t e r o i d hormones i s c o n t r o v e r s i a l . The measurement of d i f f e r e n t adrenal androgens has not given the awaited u s e f u l r e s u l t s (1). The same has been seen f o r s i n g l e plasma-ACTH-levels (2). This study has measurgd thg oplasma-ACTH-l e v e l s at d i f f e r e n t times during the day (08 ,12 ,18 ,24 ) to assess the t h e r a p e u t i c a l value o f 2 d i f f e r e n t c o r t i c o s t e r o i d s , c o r ^ j s o l ^F) and Qprednisone (P), usu a l l y given 3 times d a i l y (08 ,13 ,21 ). In a d d i t i o n , in the pat i e n t s with s a l t l o s s , 9 a - F - c o r t i s o l was given. The d i u r n a l v a r i a t i o n of plasma-ACTH and 17ct-0H-progesterone (17-OHP) and F was examined i n 20 pa-t i e n t s , 9 of which were re-examined a f t e r a l t e r a t i o n of therapy. Plasma-ACTH was measured by radioimmunoassay (RIA) a f t e r extrac-t i o n (3). Plasma s t e r o i d s were measured by RIA a f t e r p r i o r chromatography on Sephadex LH-20 columns (4). RESULTS : ACTH-levels were on the whole glevated, with maximal values at 08°°, f a l l i n g to a minimum at 24 °. There was a s i g n i -f i c a n t c o r r e l a t i o n between ACTH-levels and 17-OHP (n=114) a f t e r a logarithmic transformation (r=0.639, p<0.001) and an inverse c o r r e l a t i o n between ACTH and F (n=114, r= -0.255, p<0.01). For a b e t t e r comparison between d i f f e r e n t p a t i e n t s , the i n t e g r a l (I) under the ACTH curve over a 24h period was used (1= J " 2 4 ACTH (t) dt = X pg/ml ACTH). The value of I in CAH-patients ï n most cases' was much higher than in normals (I: 400-900, n=4). In F-treated p a t i e n t s I ranged from 220-8000 (n=17), in P-treated patients from 580-12100 (n=12), which was no s i g n i f i c a n t d i f f e r e n c e . The r a t i o F:P (given dose in mg) was 4-5 : 1. A better comparison i s obtained when I was c a l c u l a t e d f o r each p a t i e n t , who has under-gone both F and P treatment (n=5). In 4 of these p a t i e n t s I i s much lower under F, whereas in the remaining one, under 12.5 mg F/day I = 5700, under 3 mg P/day I = 2573. In a f u r t h e r 4 pa-t i e n t s under d i f f e r i n g doses of the same c o r t i c o s t e r o i d i t was oo found that in p a r t i c u l a r the evening dose (21 ) must not be too low, otherwise the ACTH-level on the following day (08 ) was exc e s s i v e l y high. CONCLUSION : The use of the ACTH-24h-integral, as described here, appears to be promising in the evaluation of therapy in CAH-patients. Furthermore the use of t h i s parameter in the same pat i e n t s r e c e i v i n g d i f f e r e n t c o r t i c o s t e r o i d s helps in the choice of t h e i r "optimal" medication. + Supported by the Deutsche Forschungsgemeinschaft (Sonder-forschungsbereich 51) and S t i f t u n g Volkswagenwerk (Az: 140194). 1) Korth-Schutz S. et a l . : J.Clin.Endocrinol.Metab.46 (1978) 452 2) Pham-Huu-Trung M.T. et a l . : J.Clin.Endocrinol.Metab.47(1978) 3) Müller O.A.et a l . : GIT Labormedizin 2 (1978) 117 4 2 2 4) Bidlingmaier F. et a l . : Pediatr.Res. 7 (1973) 901 49 

https://epub.ub.uni-muenchen.de/9253/1/9253.pdf

Diurnal plasma-ACTH-levels in corticosteroid treated patients with congenital adrenal hyperplasia (CAH)

Abstract

Similar works

Full text

Available Versions

Universität München: Elektronischen Publikationen

Open Access LMU